This preprint is under consideration at BMC Pediatrics. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Shunying Zhao
Beijing Children’s Hospital Affiliated to Capital Medical University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Since public awareness of cystic fibrosis (CF) has increased, more children have been diagnosed with CF in China. This study aimed to investigate medical and other challenges faced by pediatric CF patients in China.
Method: Treatments and treatment outcomes were retrospectively analyzed for 46 pediatric CF patients diagnosed from August 2009 to June 2019.
Results: Of 46 pediatric CF study patients, four died (one of pulmonary infection, one of severe respiratory failure, two of unknown causes) and five were lost to follow-up. Thirty-seven patients were monitored for 0.03 to 9.21 years; patients exhibited fewer attacks of respiratory tract infections after diagnosis (4.49 ± 2.13 episodes/year before diagnosis VS 1.97 ± 1.87 times/year after 1-year treatment, p < 0.05), significantly reduced sputum production and experienced 1.62 ± 1.71 exacerbations/year. Patient mean body mass index was 16.87 ± 3.53 and pancreatic malfunction persisted in 15 patients. Of the 28 children older than 6 years of age, 17 received lung function tests during follow-up; no significant differences were observed between lung function at follow-up and at diagnosis (FEV1: 82.45% ± 16.56% vs 75.26% ± 22.34%, FVC: 87.18% ± 13.64% vs 86.99% ± 19.95%, FEF75%: 46.51% ± 28.78% vs 36.63% ± 24.30%, P = 0.27, 0.97, 0.20, respectively). In 27 cases with sputum results at follow-up, Pseudomonas aeruginosa was detected in 17 (62.97%), persisted in 14, newly emerged in 3 and was eliminated in 5 cases. Computed tomography lung scans of 22 cases revealed increased bronchiectasis in 6 cases after 2-60 months of treatment, decreased bronchiectasis in 3 cases after 2-96 months of treatment and unchanged bronchiectasis in 13 cases treated for 5-60 months. Twenty-four patients complied with aerosolized therapy, azithromycin, pancreatic enzymes and nutritional intake-based treatments, while 9 patients once stopped aerosolized therapy or azithromycin and 4 patients stopped all medications. Overall, azithromycin and tobramycin treatments were administered for 0.5-62 months and 0.5-48 months, respectively, and triggered no obvious adverse reactions.
Conclusion: No obvious deterioration of clinical presentation or lung function were found in Chinese pediatric CF patients after receiving standard therapeutic and active treatments, although malnutrition and low compliance were persistent challenges.
Keywords
cystic fibrosis, follow-up, Chinese children
No competing interests reported.
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 10 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 19 Mar, 2021
Review #2 received
Received 08 Mar, 2021
Review #4 received
Received 08 Mar, 2021
Review #3 received
Received 08 Mar, 2021
Review #1 received
Received 08 Mar, 2021
Review #5 received
Received 08 Mar, 2021
Reviewer #1 agreed
On 04 Mar, 2021
Reviewer #7 agreed
On 04 Mar, 2021
Reviewer #3 agreed
On 04 Mar, 2021
Reviewer #2 agreed
On 04 Mar, 2021
Reviewer #5 agreed
On 04 Mar, 2021
Reviewer #9 agreed
On 04 Mar, 2021
Reviewer #8 agreed
On 04 Mar, 2021
Reviewer #6 agreed
On 04 Mar, 2021
Reviewer #10 agreed
On 04 Mar, 2021
Reviewer #4 agreed
On 04 Mar, 2021
Reviewers invited
Invitations sent on 04 Mar, 2021
Editor assigned
On 04 Mar, 2021
Editor invited
On 03 Mar, 2021
Submission checks complete
On 03 Mar, 2021
First submitted
On 22 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Pediatrics
Learn more about our company.
This preprint is under consideration at BMC Pediatrics. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Shunying Zhao
Beijing Children’s Hospital Affiliated to Capital Medical University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 10 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 19 Mar, 2021
Review #2 received
Received 08 Mar, 2021
Review #4 received
Received 08 Mar, 2021
Review #3 received
Received 08 Mar, 2021
Review #1 received
Received 08 Mar, 2021
Review #5 received
Received 08 Mar, 2021
Reviewer #1 agreed
On 04 Mar, 2021
Reviewer #7 agreed
On 04 Mar, 2021
Reviewer #3 agreed
On 04 Mar, 2021
Reviewer #2 agreed
On 04 Mar, 2021
Reviewer #5 agreed
On 04 Mar, 2021
Reviewer #9 agreed
On 04 Mar, 2021
Reviewer #8 agreed
On 04 Mar, 2021
Reviewer #6 agreed
On 04 Mar, 2021
Reviewer #10 agreed
On 04 Mar, 2021
Reviewer #4 agreed
On 04 Mar, 2021
Reviewers invited
Invitations sent on 04 Mar, 2021
Editor assigned
On 04 Mar, 2021
Editor invited
On 03 Mar, 2021
Submission checks complete
On 03 Mar, 2021
First submitted
On 22 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Pediatrics
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Since public awareness of cystic fibrosis (CF) has increased, more children have been diagnosed with CF in China. This study aimed to investigate medical and other challenges faced by pediatric CF patients in China.
Method: Treatments and treatment outcomes were retrospectively analyzed for 46 pediatric CF patients diagnosed from August 2009 to June 2019.
Results: Of 46 pediatric CF study patients, four died (one of pulmonary infection, one of severe respiratory failure, two of unknown causes) and five were lost to follow-up. Thirty-seven patients were monitored for 0.03 to 9.21 years; patients exhibited fewer attacks of respiratory tract infections after diagnosis (4.49 ± 2.13 episodes/year before diagnosis VS 1.97 ± 1.87 times/year after 1-year treatment, p < 0.05), significantly reduced sputum production and experienced 1.62 ± 1.71 exacerbations/year. Patient mean body mass index was 16.87 ± 3.53 and pancreatic malfunction persisted in 15 patients. Of the 28 children older than 6 years of age, 17 received lung function tests during follow-up; no significant differences were observed between lung function at follow-up and at diagnosis (FEV1: 82.45% ± 16.56% vs 75.26% ± 22.34%, FVC: 87.18% ± 13.64% vs 86.99% ± 19.95%, FEF75%: 46.51% ± 28.78% vs 36.63% ± 24.30%, P = 0.27, 0.97, 0.20, respectively). In 27 cases with sputum results at follow-up, Pseudomonas aeruginosa was detected in 17 (62.97%), persisted in 14, newly emerged in 3 and was eliminated in 5 cases. Computed tomography lung scans of 22 cases revealed increased bronchiectasis in 6 cases after 2-60 months of treatment, decreased bronchiectasis in 3 cases after 2-96 months of treatment and unchanged bronchiectasis in 13 cases treated for 5-60 months. Twenty-four patients complied with aerosolized therapy, azithromycin, pancreatic enzymes and nutritional intake-based treatments, while 9 patients once stopped aerosolized therapy or azithromycin and 4 patients stopped all medications. Overall, azithromycin and tobramycin treatments were administered for 0.5-62 months and 0.5-48 months, respectively, and triggered no obvious adverse reactions.
Conclusion: No obvious deterioration of clinical presentation or lung function were found in Chinese pediatric CF patients after receiving standard therapeutic and active treatments, although malnutrition and low compliance were persistent challenges.
Loading...